Articol
Merck and Bayer's heart drug meets main goal of late-stage study
Experimental treatment being developed for patients with worsening chronic heart failure met the main goal of a late-stage study, Merck & Co and Bayer announced.
The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients with worsening chronic heart failure compared to placebo when given in combination with available therapies for the condition, Reuters reported.
Comentarii